STOCK TITAN

Palatin Technologies, Inc. - PTN STOCK NEWS

Welcome to our dedicated page for Palatin Technologies news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Technologies stock.

Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company based in Cranbury, New Jersey. The company focuses on developing first-in-class medicines that target the melanocortin and natriuretic peptide receptor systems. These therapies are aimed at treating a variety of diseases with significant unmet medical needs and commercial potential.

The company's lead product is Vyleesi, a melanocortin receptor agonist for premenopausal women suffering from hypoactive sexual desire disorder (HSDD). Recently, Palatin announced the divestiture of Vyleesi to better focus on its robust development and clinical pipeline.

Palatin is also advancing several promising candidates through clinical trials:

  • PL9643: A melanocortin receptor agonist for treating dry eye disease (DED). The company recently reported successful results from its Phase 3 MELODY-1 trial, demonstrating significant efficacy and safety.
  • PL8177: This selective melanocortin receptor 1 (MC1R) agonist peptide has completed Phase 1 trials for inflammatory bowel diseases and systemic non-infectious uveitis. It is being further developed for treating COVID-19.
  • PL3994: A natriuretic peptide receptor (NPR)-A agonist aimed at treating cardiovascular diseases and other conditions.

Palatin’s strategic focus is on developing targeted, receptor-specific product candidates and forming marketing collaborations with industry leaders to maximize their commercial potential. The company's research and development efforts are guided by a commitment to innovative science and a focus on areas with high probability of success and differentiation.

Financially, Palatin has shown strong operational progress. As of the latest fiscal quarter, the company announced a substantial cash position, ensuring the funding of its ongoing projects into the second half of 2024. The company's leadership believes that their internal research and development efforts, concentrating on melanocortin receptor-based therapies, hold significant promise for the treatment of various conditions, including obesity and erectile dysfunction.

Palatin’s approach to biopharmaceutical development underscores a commitment to addressing significant medical needs through innovative receptor-specific therapies. For more information, visit www.Palatin.com and follow them on Twitter at @PalatinTech.

Rhea-AI Summary

Palatin Technologies (NYSE: PTN) announced positive topline data from its Phase IIb BREAKOUT study evaluating bremelanotide in patients with Type 2 diabetic nephropathy. The study, which enrolled 16 patients with 8 completing the six-month treatment, demonstrated significant efficacy:

- 71% of patients achieved >30% reduction in urine protein to creatinine ratio
- 71% achieved improved or stabilized estimated glomerular filtration rate
- 37.5% showed increased urinary VEGF levels
- 36% demonstrated reduced urinary synaptopodin losses

The treatment was well-tolerated with no serious adverse events, though skin hyperpigmentation occurred in 71% of patients. The study validates melanocortin system modulation as a potential new therapeutic strategy for this progressive kidney disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.67%
Tags
-
Rhea-AI Summary

Palatin Technologies (NYSE American: PTN) has secured approximately $3.4 million in gross proceeds through a warrant exercise agreement with an institutional investor. The agreement involves the exercise of warrants from June 2024 and October 2023, totaling 3,907,679 shares at an amended exercise price of $0.875 per share.

As part of the inducement agreement, Palatin will issue new unregistered Series C warrants for 3,907,679 shares and Series D warrants for 1,953,839 shares, both with an exercise price of $0.875. Series C warrants are immediately exercisable with a 5-year expiration, while Series D warrants require stockholder approval. The transaction is expected to close around December 17, 2024, with proceeds intended for working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
none
-
Rhea-AI Summary

Palatin Technologies (NYSE American: PTN) has completed patient enrollment in its Phase 2 study of PL8177, an oral melanocortin-1 receptor agonist, for ulcerative colitis treatment. The study involves 13 subjects and evaluates safety, efficacy, and other parameters of the drug. Topline data is expected in Q1 2025. PL8177, delivered as a once-daily pill, targets inflammation without immunosuppression, potentially offering a safer alternative to current treatments. The company aims to out-license the UC program, noting significant interest from multiple parties. Preclinical data showed PL8177's effectiveness in improving colon health and resolving inflammation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.58%
Tags
Rhea-AI Summary

Palatin Technologies (NYSE: PTN) reported Q1 FY2025 financial results and provided updates on its obesity programs. The company completed patient enrollment in October 2024 for its Phase 2 BMT-801 clinical study, combining MC4R agonist bremelanotide with GLP-1/GIP dual agonist tirzepatide, with topline results expected in Q1 2025. Net loss for Q1 was $7.8 million ($0.39 per share), compared to $5.2 million ($0.43 per share) in Q1 FY2024. Cash position as of September 30, 2024, was $2.4 million. The company has engaged an investment bank to explore strategic options for non-obesity programs, including its Phase 3 DED program and Phase 2 UC program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.08%
Tags
-
Rhea-AI Summary

Palatin Technologies (NYSE American: PTN) has announced it will release its first quarter fiscal year 2025 financial results on November 14, 2024, before U.S. markets open. The company will host a conference call and webcast at 11:00 a.m. ET the same day, featuring executive management's review of operating results and development program updates. The earnings release is scheduled for 7:30 a.m. ET, with a conference call replay available until November 28, 2024. Palatin is a biopharmaceutical company focused on developing first-in-class medicines based on melanocortin receptor systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.07%
Tags
conferences earnings
-
Rhea-AI Summary

Palatin Technologies (NYSE American: PTN) presented preclinical data for PL7737, their oral melanocortin 4 receptor (MC4R) selective agonist for obesity treatment. Studies showed that PL7737 significantly reduced food intake and body weight in diet-induced obese mice, validating its MC4R-mediated effects. The compound demonstrated promising oral bioavailability and lacked erectogenic activity, making it potentially suitable for obesity treatment.

The company plans multiple clinical trials in 2025 for its obesity programs, including novel long-acting MC4R peptide and small molecule compounds. Additionally, Palatin is conducting a Phase 2 trial combining bremelanotide with tirzepatide, with topline results expected in Q1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
Rhea-AI Summary

Palatin Technologies (NYSE American: PTN) has completed enrollment in its Phase 2 clinical study evaluating bremelanotide co-administered with tirzepatide for obesity treatment. The study enrolled approximately 120 patients, double the target, across four US sites. Topline results are expected by March 2025.

The study aims to demonstrate that combining an MC4R agonist with GLP-1/GIP may produce synergistic effects on weight loss at lower, better-tolerated doses. This research addresses the current challenges with GLP-1/GIP therapies, where 67% of patients discontinue treatment due to side effects and experience weight rebound after plateauing in the first year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
-
Rhea-AI Summary

Palatin Technologies (NYSE American: PTN) presented clinical and preclinical data on three melanocortin agonists at the 19th Annual Peptide Therapeutics Symposium. The presentation highlighted: PL9643 showing statistical significance in treating dry eye disease; PL8177 demonstrating effectiveness in reducing colonic damage and inflammation in ulcerative colitis models; and PL9654 showing promise in treating retinal diseases by reducing vision loss and photoreceptor degeneration. The data supports using melanocortin agonists to treat inflammatory diseases without immunosuppression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
Rhea-AI Summary

Palatin Technologies (NYSE American: PTN) presented foundational data on novel and highly selective Melanocortin 4 Receptor (MC4R) agonists at the 19th Annual Peptide Therapeutics Symposium. The company has identified specific structural components responsible for MC1R agonism, which causes increased skin pigmentation, and modified them to optimize MC4R activity while reducing MC1R activity. This breakthrough could potentially eliminate skin color changes in obesity treatments.

The company plans to begin clinical development in 2025, targeting obesity treatment. Currently, Palatin is conducting a Phase 2 clinical trial combining bremelanotide with tirzepatide in obese patients, with results expected in Q1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
Rhea-AI Summary

Palatin Technologies, Inc. (NYSE American: PTN) has received a notice of non-compliance from NYSE American regarding continued listing standards. The company does not meet the requirement of having stockholders' equity of $6 million or more, as specified in Section 1003(a)(iii) of the NYSE American Company Guide. This is in addition to previously reported non-compliance with Sections 1003(a)(i) and (ii).

Palatin has submitted a plan to regain compliance by April 10, 2025, which has been accepted by the Exchange. The company can continue its listing during this period, subject to periodic reviews. Palatin is exploring multiple funding avenues to achieve compliance. The notice does not immediately affect the listing or trading of Palatin's common stock, nor does it impact the company's business operations or SEC reporting requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none

FAQ

What is the current stock price of Palatin Technologies (PTN)?

The current stock price of Palatin Technologies (PTN) is $0.97 as of December 23, 2024.

What is the market cap of Palatin Technologies (PTN)?

The market cap of Palatin Technologies (PTN) is approximately 24.6M.

What is Palatin Technologies' lead product?

Palatin Technologies' lead product is Vyleesi, a melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

What are Palatin Technologies' main areas of focus?

Palatin focuses on developing first-in-class medicines for diseases with significant unmet medical needs, specifically targeting the melanocortin and natriuretic peptide receptor systems.

What is PL9643, and what is it used for?

PL9643 is a melanocortin receptor agonist developed by Palatin Technologies for treating dry eye disease (DED). It has shown significant efficacy and safety in Phase 3 clinical trials.

What other products are in Palatin Technologies' pipeline?

Palatin is developing several other products, including PL8177 for inflammatory bowel diseases and COVID-19, and PL3994 for treating cardiovascular diseases.

What recent financial highlights has Palatin Technologies announced?

Palatin announced a strong cash position as of their latest fiscal quarter, ensuring the funding of ongoing projects into the second half of 2024.

How does Palatin Technologies plan to maximize the commercial potential of its products?

Palatin plans to form marketing collaborations with industry leaders to maximize the commercial potential of its targeted, receptor-specific product candidates.

What are some recent achievements of Palatin Technologies?

Recent achievements include successful Phase 3 trial results for PL9643 in treating dry eye disease and the divestiture of Vyleesi to focus on their clinical pipeline.

What is the significance of melanocortin receptor agonists in Palatin's research?

Melanocortin receptor agonists, which Palatin specializes in, have effects on inflammation, immune responses, metabolism, food intake, and sexual function, making them significant for various treatments.

What partnerships has Palatin Technologies formed?

Palatin’s strategy includes forming collaborations with industry leaders to maximize the commercial potential of its products, though specific partners are not mentioned in the latest updates.

How can one learn more about Palatin Technologies?

For more information, visit Palatin's website at www.Palatin.com and follow them on Twitter at @PalatinTech.

Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Stock Data

24.63M
18.86M
3.5%
7.88%
5.99%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CRANBURY